A REGISTRY-BASED, OBSERVATIONAL SAFETY STUDY OF INOTUZUMAB OZOGAMICIN (INO) IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PROCEEDING TO HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)

Objective: InO is a CD22-directed antibody-drug conjugate indicated for treatment of relapsed/refractory (R/R) ALL. InO has been associated with hepatotoxicity and hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS), particularly post-HSCT. Registry data from the Center for Inte...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	David MARKS, Marcos DE LIMA, Partow KEBRIAEI, Francesco LANZA, Christina CHO, Sergio GIRALT, Gizelle POPRADI, Michael HEMMER, Wael SABER, Xin ZHANG, Richa SHAH, Verna WELCH, Erik VANDENDRIES, Matthias STELLJES
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/f431a58aacfd4959a47594143e1bfe9f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f431a58aacfd4959a47594143e1bfe9f
record_format	dspace
spelling	oai:doaj.org-article:f431a58aacfd4959a47594143e1bfe9f2021-11-10T04:34:38ZA REGISTRY-BASED, OBSERVATIONAL SAFETY STUDY OF INOTUZUMAB OZOGAMICIN (INO) IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PROCEEDING TO HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)2531-137910.1016/j.htct.2021.10.1013https://doaj.org/article/f431a58aacfd4959a47594143e1bfe9f2021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2531137921011603https://doaj.org/toc/2531-1379Objective: InO is a CD22-directed antibody-drug conjugate indicated for treatment of relapsed/refractory (R/R) ALL. InO has been associated with hepatotoxicity and hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS), particularly post-HSCT. Registry data from the Center for International Blood and Marrow Transplant Research (CIBMTR) was analyzed to assess toxicity in patients (pts) with ALL who received InO prior to HSCT. Methodology: CIBMTR patient data are being collected from 2017-2022 after US approval of InO. Data accrued from 2017–2020 from 131 US adult pts (median age 40 y) treated with InO who proceeded to allogeneic HSCT were included. Using interim data at 3 y, we evaluated post-HSCT outcomes, including clinical status, overall survival (OS), non-relapse mortality (NRM), relapse, death after relapse, and investigator-defined adverse events, including hepatic VOD/SOS. All statistical analyses are descriptive. Results: Before HSCT, 36% of pts received 1 InO cycle, 46% had 2 cycles, 17% had ≥3 cycles. Median time from last InO dose to HSCT was 2.0 mos (range: 0.4–26.2). At data lock (Nov 2020, n=131), VOD/SOS incidence within 100 d post-HSCT was 13% (18% of R/R ALL pts, n=91). Post-HSCT 12 mo OS was 55%; post-HSCT 12 mo NRM was 21%; post-HSCT 12 mo relapse was 36%; non-HSCT-related 12 mo mortality was 25%. Most pts (89%) who underwent HSCT during complete remission (CR) experienced continued CR post-HSCT. Conclusion: Incidence of VOD/SOS after first HSCT in InO-treated pts with R/R ALL in this study was similar to the 18-19% reported in pooled analyses of 2 clinical trials among InO-treated pts with R/R ALL and in the INO-VATE study. The NRM at 1 y of 21% (23% R/R ALL) is lower than the NRM at 1 y of 38% reported in the pooled analyses of R/R ALL InO recipients. © 2021 American Society of Clinical Oncology, Inc. Reused with permission. Accepted/presented at the 2021 ASCO Annual Meeting. All rights reserved.David MARKSMarcos DE LIMAPartow KEBRIAEIFrancesco LANZAChristina CHOSergio GIRALTGizelle POPRADIMichael HEMMERWael SABERXin ZHANGRicha SHAHVerna WELCHErik VANDENDRIESMatthias STELLJESElsevierarticleDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S34- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 David MARKS Marcos DE LIMA Partow KEBRIAEI Francesco LANZA Christina CHO Sergio GIRALT Gizelle POPRADI Michael HEMMER Wael SABER Xin ZHANG Richa SHAH Verna WELCH Erik VANDENDRIES Matthias STELLJES A REGISTRY-BASED, OBSERVATIONAL SAFETY STUDY OF INOTUZUMAB OZOGAMICIN (INO) IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PROCEEDING TO HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
description	Objective: InO is a CD22-directed antibody-drug conjugate indicated for treatment of relapsed/refractory (R/R) ALL. InO has been associated with hepatotoxicity and hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS), particularly post-HSCT. Registry data from the Center for International Blood and Marrow Transplant Research (CIBMTR) was analyzed to assess toxicity in patients (pts) with ALL who received InO prior to HSCT. Methodology: CIBMTR patient data are being collected from 2017-2022 after US approval of InO. Data accrued from 2017–2020 from 131 US adult pts (median age 40 y) treated with InO who proceeded to allogeneic HSCT were included. Using interim data at 3 y, we evaluated post-HSCT outcomes, including clinical status, overall survival (OS), non-relapse mortality (NRM), relapse, death after relapse, and investigator-defined adverse events, including hepatic VOD/SOS. All statistical analyses are descriptive. Results: Before HSCT, 36% of pts received 1 InO cycle, 46% had 2 cycles, 17% had ≥3 cycles. Median time from last InO dose to HSCT was 2.0 mos (range: 0.4–26.2). At data lock (Nov 2020, n=131), VOD/SOS incidence within 100 d post-HSCT was 13% (18% of R/R ALL pts, n=91). Post-HSCT 12 mo OS was 55%; post-HSCT 12 mo NRM was 21%; post-HSCT 12 mo relapse was 36%; non-HSCT-related 12 mo mortality was 25%. Most pts (89%) who underwent HSCT during complete remission (CR) experienced continued CR post-HSCT. Conclusion: Incidence of VOD/SOS after first HSCT in InO-treated pts with R/R ALL in this study was similar to the 18-19% reported in pooled analyses of 2 clinical trials among InO-treated pts with R/R ALL and in the INO-VATE study. The NRM at 1 y of 21% (23% R/R ALL) is lower than the NRM at 1 y of 38% reported in the pooled analyses of R/R ALL InO recipients. © 2021 American Society of Clinical Oncology, Inc. Reused with permission. Accepted/presented at the 2021 ASCO Annual Meeting. All rights reserved.
format	article
author	David MARKS Marcos DE LIMA Partow KEBRIAEI Francesco LANZA Christina CHO Sergio GIRALT Gizelle POPRADI Michael HEMMER Wael SABER Xin ZHANG Richa SHAH Verna WELCH Erik VANDENDRIES Matthias STELLJES
author_facet	David MARKS Marcos DE LIMA Partow KEBRIAEI Francesco LANZA Christina CHO Sergio GIRALT Gizelle POPRADI Michael HEMMER Wael SABER Xin ZHANG Richa SHAH Verna WELCH Erik VANDENDRIES Matthias STELLJES
author_sort	David MARKS
title	A REGISTRY-BASED, OBSERVATIONAL SAFETY STUDY OF INOTUZUMAB OZOGAMICIN (INO) IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PROCEEDING TO HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
title_short	A REGISTRY-BASED, OBSERVATIONAL SAFETY STUDY OF INOTUZUMAB OZOGAMICIN (INO) IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PROCEEDING TO HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
title_full	A REGISTRY-BASED, OBSERVATIONAL SAFETY STUDY OF INOTUZUMAB OZOGAMICIN (INO) IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PROCEEDING TO HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
title_fullStr	A REGISTRY-BASED, OBSERVATIONAL SAFETY STUDY OF INOTUZUMAB OZOGAMICIN (INO) IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PROCEEDING TO HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
title_full_unstemmed	A REGISTRY-BASED, OBSERVATIONAL SAFETY STUDY OF INOTUZUMAB OZOGAMICIN (INO) IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PROCEEDING TO HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
title_sort	registry-based, observational safety study of inotuzumab ozogamicin (ino) in patients with b-cell precursor acute lymphoblastic leukemia (all) proceeding to hematopoietic stem cell transplant (hsct)
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/f431a58aacfd4959a47594143e1bfe9f
work_keys_str_mv	AT davidmarks aregistrybasedobservationalsafetystudyofinotuzumabozogamicininoinpatientswithbcellprecursoracutelymphoblasticleukemiaallproceedingtohematopoieticstemcelltransplanthsct AT marcosdelima aregistrybasedobservationalsafetystudyofinotuzumabozogamicininoinpatientswithbcellprecursoracutelymphoblasticleukemiaallproceedingtohematopoieticstemcelltransplanthsct AT partowkebriaei aregistrybasedobservationalsafetystudyofinotuzumabozogamicininoinpatientswithbcellprecursoracutelymphoblasticleukemiaallproceedingtohematopoieticstemcelltransplanthsct AT francescolanza aregistrybasedobservationalsafetystudyofinotuzumabozogamicininoinpatientswithbcellprecursoracutelymphoblasticleukemiaallproceedingtohematopoieticstemcelltransplanthsct AT christinacho aregistrybasedobservationalsafetystudyofinotuzumabozogamicininoinpatientswithbcellprecursoracutelymphoblasticleukemiaallproceedingtohematopoieticstemcelltransplanthsct AT sergiogiralt aregistrybasedobservationalsafetystudyofinotuzumabozogamicininoinpatientswithbcellprecursoracutelymphoblasticleukemiaallproceedingtohematopoieticstemcelltransplanthsct AT gizellepopradi aregistrybasedobservationalsafetystudyofinotuzumabozogamicininoinpatientswithbcellprecursoracutelymphoblasticleukemiaallproceedingtohematopoieticstemcelltransplanthsct AT michaelhemmer aregistrybasedobservationalsafetystudyofinotuzumabozogamicininoinpatientswithbcellprecursoracutelymphoblasticleukemiaallproceedingtohematopoieticstemcelltransplanthsct AT waelsaber aregistrybasedobservationalsafetystudyofinotuzumabozogamicininoinpatientswithbcellprecursoracutelymphoblasticleukemiaallproceedingtohematopoieticstemcelltransplanthsct AT xinzhang aregistrybasedobservationalsafetystudyofinotuzumabozogamicininoinpatientswithbcellprecursoracutelymphoblasticleukemiaallproceedingtohematopoieticstemcelltransplanthsct AT richashah aregistrybasedobservationalsafetystudyofinotuzumabozogamicininoinpatientswithbcellprecursoracutelymphoblasticleukemiaallproceedingtohematopoieticstemcelltransplanthsct AT vernawelch aregistrybasedobservationalsafetystudyofinotuzumabozogamicininoinpatientswithbcellprecursoracutelymphoblasticleukemiaallproceedingtohematopoieticstemcelltransplanthsct AT erikvandendries aregistrybasedobservationalsafetystudyofinotuzumabozogamicininoinpatientswithbcellprecursoracutelymphoblasticleukemiaallproceedingtohematopoieticstemcelltransplanthsct AT matthiasstelljes aregistrybasedobservationalsafetystudyofinotuzumabozogamicininoinpatientswithbcellprecursoracutelymphoblasticleukemiaallproceedingtohematopoieticstemcelltransplanthsct AT davidmarks registrybasedobservationalsafetystudyofinotuzumabozogamicininoinpatientswithbcellprecursoracutelymphoblasticleukemiaallproceedingtohematopoieticstemcelltransplanthsct AT marcosdelima registrybasedobservationalsafetystudyofinotuzumabozogamicininoinpatientswithbcellprecursoracutelymphoblasticleukemiaallproceedingtohematopoieticstemcelltransplanthsct AT partowkebriaei registrybasedobservationalsafetystudyofinotuzumabozogamicininoinpatientswithbcellprecursoracutelymphoblasticleukemiaallproceedingtohematopoieticstemcelltransplanthsct AT francescolanza registrybasedobservationalsafetystudyofinotuzumabozogamicininoinpatientswithbcellprecursoracutelymphoblasticleukemiaallproceedingtohematopoieticstemcelltransplanthsct AT christinacho registrybasedobservationalsafetystudyofinotuzumabozogamicininoinpatientswithbcellprecursoracutelymphoblasticleukemiaallproceedingtohematopoieticstemcelltransplanthsct AT sergiogiralt registrybasedobservationalsafetystudyofinotuzumabozogamicininoinpatientswithbcellprecursoracutelymphoblasticleukemiaallproceedingtohematopoieticstemcelltransplanthsct AT gizellepopradi registrybasedobservationalsafetystudyofinotuzumabozogamicininoinpatientswithbcellprecursoracutelymphoblasticleukemiaallproceedingtohematopoieticstemcelltransplanthsct AT michaelhemmer registrybasedobservationalsafetystudyofinotuzumabozogamicininoinpatientswithbcellprecursoracutelymphoblasticleukemiaallproceedingtohematopoieticstemcelltransplanthsct AT waelsaber registrybasedobservationalsafetystudyofinotuzumabozogamicininoinpatientswithbcellprecursoracutelymphoblasticleukemiaallproceedingtohematopoieticstemcelltransplanthsct AT xinzhang registrybasedobservationalsafetystudyofinotuzumabozogamicininoinpatientswithbcellprecursoracutelymphoblasticleukemiaallproceedingtohematopoieticstemcelltransplanthsct AT richashah registrybasedobservationalsafetystudyofinotuzumabozogamicininoinpatientswithbcellprecursoracutelymphoblasticleukemiaallproceedingtohematopoieticstemcelltransplanthsct AT vernawelch registrybasedobservationalsafetystudyofinotuzumabozogamicininoinpatientswithbcellprecursoracutelymphoblasticleukemiaallproceedingtohematopoieticstemcelltransplanthsct AT erikvandendries registrybasedobservationalsafetystudyofinotuzumabozogamicininoinpatientswithbcellprecursoracutelymphoblasticleukemiaallproceedingtohematopoieticstemcelltransplanthsct AT matthiasstelljes registrybasedobservationalsafetystudyofinotuzumabozogamicininoinpatientswithbcellprecursoracutelymphoblasticleukemiaallproceedingtohematopoieticstemcelltransplanthsct
_version_	1718440613374853120

A REGISTRY-BASED, OBSERVATIONAL SAFETY STUDY OF INOTUZUMAB OZOGAMICIN (INO) IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PROCEEDING TO HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)

Ejemplares similares